SubHero Banner

Venclexta® (venetoclax) – New indication

November 21, 2018 - AbbVie and Roche announced the FDA approval of  Venclexta (venetoclax), in combination with azacitidine, or decitabine, or low-dose cytarabine (LDAC) for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.

Download PDF